Header Logo

Connection

Bruce Fireman to Vaccination

Back to Details
This is a "connection" page, showing publications Bruce Fireman has written about Vaccination.
Bruce Fireman
Connection Strength
2.559
Vaccination
  1. Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. Vaccine. 2010 Oct 21; 28(45):7267-72.
    View in: PubMed
    Score: 0.257
  2. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol. 2009 Sep 01; 170(5):650-6.
    View in: PubMed
    Score: 0.238
  3. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004 Jun; 23(6):485-9.
    View in: PubMed
    Score: 0.167
  4. If Influenza Vaccines Wane, Can We Delay Vaccination Without Compromising Coverage? Clin Infect Dis. 2020 04 10; 70(8):1560-1561.
    View in: PubMed
    Score: 0.125
  5. Depletion-of-susceptibles Bias in Analyses of Intra-season Waning of Influenza Vaccine Effectiveness. Clin Infect Dis. 2020 03 17; 70(7):1484-1486.
    View in: PubMed
    Score: 0.124
  6. Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season. PLoS One. 2020; 15(2):e0229279.
    View in: PubMed
    Score: 0.124
  7. Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis. Pediatrics. 2017 May; 139(5).
    View in: PubMed
    Score: 0.101
  8. Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder. JAMA Pediatr. 2017 Jan 02; 171(1):e163609.
    View in: PubMed
    Score: 0.100
  9. Waning Tdap Effectiveness in Adolescents. Pediatrics. 2016 Mar; 137(3):e20153326.
    View in: PubMed
    Score: 0.094
  10. Impact of vaccination on the epidemiology of varicella: 1995-2009. Pediatrics. 2014 Jul; 134(1):24-30.
    View in: PubMed
    Score: 0.083
  11. Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011. PLoS One. 2013; 8(6):e67185.
    View in: PubMed
    Score: 0.078
  12. Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis. 2013 Jul; 57(2):197-204.
    View in: PubMed
    Score: 0.077
  13. Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine. 2012 Dec 17; 31(1):271-7.
    View in: PubMed
    Score: 0.073
  14. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010 Jul; 126(1):e1-8.
    View in: PubMed
    Score: 0.063
  15. Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection. Nat Commun. 2024 Nov 20; 15(1):10062.
    View in: PubMed
    Score: 0.043
  16. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.042
  17. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 28; 73(12):271-276.
    View in: PubMed
    Score: 0.041
  18. Mortality risk after COVID-19 vaccination: A self-controlled case series study. Vaccine. 2024 Mar 07; 42(7):1731-1737.
    View in: PubMed
    Score: 0.041
  19. Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records. BMJ. 2023 Nov 08; 383:e076321.
    View in: PubMed
    Score: 0.040
  20. Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink. Vaccine. 2023 08 14; 41(36):5265-5270.
    View in: PubMed
    Score: 0.039
  21. Safety of COVID-19 mRNA Vaccination Among Young Children in the Vaccine Safety Datalink. Pediatrics. 2023 Jul 01; 152(1).
    View in: PubMed
    Score: 0.039
  22. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics. 2023 05 01; 151(5).
    View in: PubMed
    Score: 0.039
  23. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023 03 01; 6(3):e232598.
    View in: PubMed
    Score: 0.038
  24. Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life. Nat Commun. 2023 Feb 28; 14(1):894.
    View in: PubMed
    Score: 0.038
  25. A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination. Vaccine. 2023 01 16; 41(3):844-854.
    View in: PubMed
    Score: 0.038
  26. Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States. Ann Intern Med. 2022 12; 175(12):1169-1771.
    View in: PubMed
    Score: 0.037
  27. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022 08 19; 40(35):5153-5159.
    View in: PubMed
    Score: 0.037
  28. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines. Vaccine. 2022 Jul 30; 40(32):4663-4671.
    View in: PubMed
    Score: 0.036
  29. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Netw Open. 2022 04 01; 5(4):e228879.
    View in: PubMed
    Score: 0.036
  30. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021. Am J Transplant. 2022 01; 22(1):306-314.
    View in: PubMed
    Score: 0.035
  31. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 1999 Sep; 18(9):757-63.
    View in: PubMed
    Score: 0.030
  32. Live Attenuated Influenza Vaccination Before 3 Years of Age and Subsequent Development of Asthma: A 14-year Follow-up Study. Pediatr Infect Dis J. 2018 05; 37(5):383-386.
    View in: PubMed
    Score: 0.027
  33. No association between influenza vaccination during pregnancy and adverse birth outcomes. Vaccine. 2017 05 31; 35(24):3186-3190.
    View in: PubMed
    Score: 0.026
  34. Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. Clin Infect Dis. 2016 Dec 01; 63(11):1456-1462.
    View in: PubMed
    Score: 0.024
  35. Case-centered Analysis of Optic Neuritis After Vaccines. Clin Infect Dis. 2016 07 01; 63(1):79-81.
    View in: PubMed
    Score: 0.024
  36. Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study. Pediatrics. 2013 May; 131(5):e1389-96.
    View in: PubMed
    Score: 0.019
  37. Safety of Zostavax™--a cohort study in a managed care organization. Vaccine. 2012 Oct 19; 30(47):6636-41.
    View in: PubMed
    Score: 0.018
  38. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics. 2011 May; 127 Suppl 1:S54-64.
    View in: PubMed
    Score: 0.017
  39. Evaluation of immunization rates and safety among children with inborn errors of metabolism. Pediatrics. 2011 May; 127(5):e1139-46.
    View in: PubMed
    Score: 0.017
  40. A role for genetics in the immune response to the varicella vaccine. Pediatr Infect Dis J. 2007 Apr; 26(4):300-5.
    View in: PubMed
    Score: 0.013
  41. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J. 2006 Jun; 25(6):494-501.
    View in: PubMed
    Score: 0.012
  42. Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J. 1991 Feb; 10(2):92-6.
    View in: PubMed
    Score: 0.004
  43. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J. 1991 Feb; 10(2):97-104.
    View in: PubMed
    Score: 0.004

© 2024 Kaiser Permanente